Sign up to save your podcasts
Or
Share Episode 32: Pfizer Finds Home For Upjohn, Though Lessened Diversity Results In Lower Rating
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Episode 32: Pfizer Finds Home For Upjohn, Though Lessened Diversity Results In Lower Rating
The S&P Pharma Guy, Arthur Wong, shares S&P Global's thoughts on Pfizer Inc.'s announcement it was spinning off Upjohn, home to legacy products Lipitor, Viagra, and Lyrica. Pfizer remains a pharma giant and leading player in the industry. However, the lessened diversity will result in a lower rating.
View all episodes
By SP Global RatingsThe S&P Pharma Guy, Arthur Wong, shares S&P Global's thoughts on Pfizer Inc.'s announcement it was spinning off Upjohn, home to legacy products Lipitor, Viagra, and Lyrica. Pfizer remains a pharma giant and leading player in the industry. However, the lessened diversity will result in a lower rating.